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ABSTRACT
Indirect evidence in the nonhuman primate and human suggests
that angiogenesis and regulators of angiogenesis such as vascular
endothelial growth factor (VEGF) may play an active role in cyclic
folliculogenesis. Indeed, the follicle selected for maturation and ovu-
lation possesses a denser microvascular network, and VEGF mes-
senger ribonucleic acid and its protein have been identified in gran-
ulosa cells of the developing follicle during the mid- and late follicular
phases, with a more intense signal in the mature follicle. The objective
of this study was to obtain direct evidence in the nonhuman primate
for an active role of VEGF in follicular growth and maturation by
studying the effect of VEGF-blocking antibodies in this process. After
documenting two normal ovulatory cycles, female rhesus monkeys
(n 5 7) received iv injections of anti-VEGF antibodies (0.5 mg) twice
on successive days in the late follicular phase. Three monkeys also
received nonspecific goat IgG (0.5 mg) twice on successive days in the
late follicular phase. Daily measurements of estradiol, progesterone,
LH, and FSH were obtained during the two control cycles, the anti-
VEGF treatment and posttreatment cycles, and the IgG treatment
cycle. Anti-VEGF antibody administration significantly lengthened
the follicular phase in six of seven monkeys to 17.8 6 1.7 vs. 10.0 6
0.7 and 9.8 6 0.6 in control cycles and 10.7 6 0.3 days (mean 6 SE)
in IgG-treated cycles. The expected late follicular phase rise in es-
tradiol, as documented in the control cycles (day 0, 96.1 6 6.0; day 1,
125.5 6 20.0; day 2, 165.5 6 24.9; day 3, 183.8 6 11.0 pg/mL), was
interrupted by anti-VEGF antibody treatment (99.3 6 5.0, day 0,
preinjection control) to 63.3 6 12.2 (day 1), 48.5 6 8.7 (day 2), and
57.6 6 9.0 (day 3). Mean FSH levels were significantly increased by
day 2 of anti-VEGF antibody treatment. After a variable delay, es-
tradiol concentrations increased to reach a preovulatory peak in all
anti-VEGF-treated animals, followed by ovulation, normal luteal
function, and a normal posttreatment cycle. The data clearly dem-
onstrate that short-term inhibition of angiogenesis with an anti-
VEGF-blocking antibody during the later growth phase of the
dominant follicle interferes with normal follicular development. Per-
sistence of estradiol secretion and delayed resumption of its rise also
suggest recovery of the follicle. We conclude that the angiogenic reg-
ulator VEGF is a crucial component in the process of follicular growth
in the primate. (J Clin Endocrinol Metab 86: 768–772, 2001)
PHYSIOLOGICALLY, ANGIOGENESIS in the adult fe-male is confined to the ovary and uterus, where it is
active during the menstrual cycle and pregnancy (1–3). Sev-
eral potential angiogenic regulators have been identified (4).
One of the most important regulator is vascular endothelial
growth factor (VEGF), which has been well demonstrated to
exert potent angiogenic activity, both in vitro and in vivo
(5–7). Indirect evidence in the primate suggests that angio-
genesis and regulators of angiogenesis may play an active
role in cyclic folliculogenesis. First, angiogenesis is initiated
early in the development of the follicle, and a complex vas-
cular network is formed within the thecal cell layer during
follicular growth (8). Importantly, the selected follicle has
been shown to possess a denser microvascular network than
that of lesser developed follicles, suggesting a more active
angiogenic process in this follicle destined for ovulation (9).
Second, in situ hybridization studies in the monkey have
demonstrated VEGF messenger ribonucleic acid to be
present in granulosa cells of the developing follicle during
the mid- and late follicular phases, with a more intense hy-
bridization signal in the mature follicle (10). In the human
ovary, VEGF receptor is detected mostly in theca interna cells
of antral and developing follicles (11–13). A greater intensity
of VEGF staining is also seen in the more mature human
follicle, whereas no activity is detected in primordial, pri-
mary follicles or atretic follicles. VEGF activity is well cor-
related with proliferating activity markers in the vascular
endothelial cells (4, 7).
Although the above data suggest a putative role of VEGF
in folliculogenesis, direct evidence for an active role of an-
giogenesis, and of VEGF in particular, in the cyclic follicular
growth and maturation process remains to be obtained. The
present study in the rhesus monkey was designed to provide
such evidence by investigating the effects of a temporary




Regularly cycling female rhesus monkeys (Macaca mulatta), weighing
4–8 kg, were used in this study. The animals were housed in individual
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cages in temperature- and light (lights on, 0730–1930 h)-controlled
rooms. They were fed Purina monkey chow (Ralston Purina Co., St.
Louis MO) twice daily and fresh fruit or vegetables. Water was available
at all times. Menstruation was determined by daily vaginal swabbing.
Blood samples were obtained by venipuncture (a process to which the
animals had been previously habituated). The experimental protocol
was approved by the animal care and use committee of Columbia
University and was performed in accordance with the NIH Guide for the
Care and Use of Laboratory Animals.
Experimental protocols
The experiment was designed to investigate in the primate the role
of angiogenesis in folliculogenesis using an anti-VEGF antibody. Two
normal control ovulatory cycles were documented before initiation of
the experiment. In the first experimental protocols, animals (n 5 7)
received iv injections of anti-VEGF antibodies (0.5 mg each day) on 2
successive days in the late follicular phase, at a time when mean estradiol
(E2) concentrations were 99.3 6 5.0 (6se; range, 74–112) pg/mL. To
monitor possible delayed effects of antibody treatment, the posttreat-
ment cycle was also investigated. Daily blood samples were drawn
throughout the entire period to monitor cyclicity in the control, treat-
ment and posttreatment cycles and to determine the effects of anti-VEGF
antibody treatment. After one normal ovulatory cycle was again doc-
umented, three of these monkeys received iv injections of nonspecific
goat IgG (0.5 mg each day) on 2 successive days in the late follicular
phase (mean E2, 97.3 6 4.1; range, 91–117 pg/mL). Daily blood samples
were similarly obtained and analyzed.
Polyclonal antihuman VEGF antibody (R&D Systems, Inc., Minne-
apolis, MN) was raised in goats immunized against recombinant human
VEGF containing 165 amino acid residues (rhVEGF165). This VEGF-
specific IgG was purified by human VEGF affinity chromatography.
[According to the manufacturer, this antibody shows no cross-reactivity
with human platelet-derived growth factors (hPDGF-AA, hPDGF-AB,
and hPDGF-BB), hVEGF B, hVEGF C, hVEGF D, human placenta growth
factor, human connective tissue growth factor, and hFlt-1, and was
selected for its ability to neutralize the biological activity of rhVEGF165
and rhVEGF121.] Purified goat IgG (Sigma, St. Louis, MO) was obtained
from pooled normal goat sera. Both lyophilized preparations were re-
constituted in physiological saline to final concentrations of 1 mg/mL,
and aliquots were stored at 270 C until use.
Assays and statistical analysis
Blood samples were centrifuged, and sera were kept at 220 C until
assay. Concentrations of E2, to assess follicular maturation, and of pro-
gesterone, to evaluate luteal phase quality, were measured in daily
serum samples by a chemiluminescent immunoassay using the Immu-
lite system (Diagnostic Products, Los Angeles, CA). Interassay coeffi-
cients of variation were 11.9% and 11.1% for E2 and progesterone, re-
spectively. To detect potential effects of the treatment on gonadotropin
secretion, LH and FSH concentrations were also measured by recom-
binant homologous RIA (14) using reagents provided by the National
Hormone and Pituitary Program. Assay sensitivity (at 95% binding) for
LH and FSH was 0.01 and 0.02 ng/tube respectively. Intra- and inter-
assay coefficients of variation were 7.0% and 13.1%, respectively, for LH
and 5.0% and 6.1% for FSH.
Cycle parameters (length of the follicular and luteal phase), hormone
concentrations, and integrated progesterone values during the luteal
phase (as calculated by trapezoidal analysis of the areas under the daily
progesterone curves) were compared in control, treatment, and post-
treatment cycles. Comparisons between control and experimental cycles
were made using multiple ANOVA, followed by the Tukey test. The
level of significance was set at P , 0.05.
Results
Menstrual cycle length
Anti-VEGF antibody administration in the late follicular
phase significantly lengthened the follicular phase in six of
seven monkeys, from 10.0 6 0.7 and 9.8 6 0.7 days (mean 6
se) in the two preceding control cycles to 17.8 6 1.7 days in
the treatment cycle. Posttreatment cycle length, however,
was similar to that in the control cycles (Table 1). One mon-
key (not included in Table 1 or Fig. 1) did not respond to the
treatment. The follicular phase in animals receiving nonspe-
cific goat IgG (n 5 3) was similar in length (10.7 6 0.3 days)
to that in the control cycle (Table 1). There were no differ-
ences in luteal phase length between control, treatment, and
posttreatment cycles (Table 1).
Hormonal response
After anti-VEGF antibody administration, E2 concentra-
tions decreased from 99.3 6 5.0 pg/mL (preinjection control
on day 0) to 63.3 6 12.2 (day 1), 48.5 6 8.7 (day 2; P , 0.01),
and 57.6 6 9.0 (day 3; P , 0.05; Fig. 1). These values contrast
with the increasing E2 concentrations observed in the same
animals during the control cycles; starting on a day of com-
parable E2 concentrations (day 0: 96.1 6 6.0), these values
increased to 125.5 6 20.0 (day 1), 165.5 6 24.9 (day 2), and
183.8 6 11.0 (day 3). Figure 1 compares mean E2 concentra-
tions in control cycles to individual E2 concentrations in six
monkeys receiving anti-VEGF antibody. After a variable de-
lay in the animals receiving anti-VEGF antibody, E2 concen-
trations increased to reach a preovulatory peak. Mean pre-
ovulatory E2 peaks were similar in control cycles (183.8 6
11.0 pg/mL), anti-VEGF-treated cycles (230 6 29.8), and
nonspecific IgG-treated cycles (187 6 17.8), respectively. All
animals had a LH surge, although it was delayed in six
monkeys treated with anti-VEGF antibody. Ovulation oc-
curred in all animals, and although appearance of the luteal
phase was delayed in animals receiving anti-VEGF antibody,
luteal function, as reflected by integrated luteal progesterone
concentrations, was comparable in the control, treatment,
and posttreatment cycles (Table 1). Basal LH and FSH con-
centrations increased in all six animals after anti-VEGF an-
tibody treatment compared with those in animals treated
with nonspecific IgG, although the increase was statistically
significant only for FSH (Table 2). No effect of nonspecific
goat IgG administration on E2 or progesterone secretion was
observed.
Figures 2 and 3 illustrate longitudinal hormone changes in
the two successive control, anti-VEGF treatment, and post-
treatment cycles and in the IgG-treated cycle in two indi-
vidual monkeys. Treatment with the specific antibody, but
not with nonspecific IgG, delayed the process of follicular
maturation by 6 days in monkey RCJ2 and by 8 days in
TABLE 1. Effects of a 2-day administration of anti-VEGF antibody during the late follicular phase on menstrual cycle parameters
Control 1 Control 2 Anti-VEGF cycle Posttreatment IgG cycle
Follicular length (days 6 SE) 10.0 6 0.7 9.8 6 0.7 17.8 6 1.7a 10.4 6 1.2 10.7 6 0.3
Luteal length (days 6 SE) 15.3 6 0.3 15.4 6 0.4 15.8 6 0.1 15.6 6 0.1 15.3 6 0.7
Luteal progesterone (ng/mL) 49.9 6 4.1 45.5 6 3.1 55.4 6 3.5 40.2 6 4.0 53.0 6 4.0
a P , 0.05 vs. controls, posttreatment, and IgG cycles.
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monkey RTC2 compared with the preceding control cycles in
the same animals.
Discussion
Our data in the primate clearly indicate that short-term
inhibition of angiogenesis after anti-VEGF antibody admin-
istration during the later growth phase of the dominant fol-
licle interferes with its normal development. This evidence,
supplemented by immunohistochemical and in situ hybrid-
ization data indicative of increasing VEGF activity (10–13)
and by the manifestation of increased capillary density (9) in
the maturing follicle, provides a direct demonstration of the
requirement for VEGF involvement and active angiogenesis
in the later stage of the normal follicular maturation process.
In this specific protocol, anti-VEGF treatment was initiated
in the late follicular phase, at a time when a dominant follicle
has already been selected and when peripheral E2 secretion
reflects the growth rate of this follicle (15–17). The facts that
the treatment interrupted the characteristic rise in E2 secre-
tion and resulted in a significant lengthening of the follicular
phase directly demonstrate that in the absence of adequate
VEGF stimulation, normal follicular maturation is interfered
with. We interpret this impediment to normal follicular
growth to be the result of a temporary interruption of local
angiogenesis. In addition, these data may reflect a reduction
in local vascular permeability, as experimental data suggest
a role for VEGF in this process (6, 7). In either case, neutral-
ization of VEGF activity would, among other effects, limit
access to the peripheral factors needed to support follicle
growth, such as, for example, the gonadotropins. It is well
known that LH and FSH are required for proper E2 secretion
(15, 16). Interestingly, data in the literature also suggest a role
for the gonadotropins in VEGF production by the follicle.
Studies with monkey granulosa cells demonstrate that not
only are large amounts of gonadotropins representative of
the midcycle ovulatory surge, but smaller amounts, more
typical of tonic secretion, enhance local VEGF production (18,
19). A similar stimulation of VEGF is seen in PMS-stimulated
rats after hCG administration (20). Furthermore, decreased
VEGF messenger ribonucleic acid expression, albeit in the
corpus luteum, is seen in the monkey after GnRH antagonist
administration. Such data confirm the dependence of local
ovarian VEGF activity on tonic gonadotropin secretion (10),
and thus, it may not be surprising that VEGF activity in-
creases in the maturing follicle in the late follicular phase.
Overall, VEGF antibody treatment may not only impede
angiogenesis directly, but also potentially decrease local
VEGF production by modifying local vascular permeability
and decreasing gonadotropin support of VEGF synthesis.
Similar effects on E2 secretion and menstrual cycle length
were reported in the human and the monkey after the ad-
ministration of a GnRH antagonist during the follicular
phase (21–23). Although this remains to be demonstrated,
such an effect of GnRH antagonist treatment on the growing
follicle may well partially reflect a local decrease in available
VEGF. The hormonal environments after GnRH antagonist
and anti-VEGF antibody treatment, however, are quite dif-
ferent. Gonadotropin levels are obviously suppressed after
antagonist administration (22), whereas our data show a
short-term increase in FSH release after anti-VEGF antibody
treatment, presumably associated with a decrease in E2 levels
and the parallel decline in the negative feedback activity of
the steroid.
Although the normal late follicular rise in E2 is interrupted
in monkeys receiving anti-VEGF antibodies, it is unlikely
that the selected maturing follicle is destroyed in this process,
because some degree of E2 secretion persists. Once E2 secre-
tion resumes, the ovulatory LH surge follows without delay
in most monkeys, as it does in the normal cycle. Thus, we
speculate that anti-VEGF antibody treatment interferes tem-
porarily with normal vascularization function in the selected
maturing follicle and that this follicle can be maintained for
several days in a suspended state. Data obtained after a 4-day
GnRH antagonist treatment in the human also support a
temporary suspension of follicle growth, as monitored by
ultrasonographic measurements of follicular diameter (21,
22). Such studies remain to be performed in our experimental
model.
This report on the effectiveness of an anti-VEGF antibody
to interfere with normal follicular development in the rhesus
parallels data in the marmoset monkey showing interference
with normal luteal phase function after VEGF neutralization
(24). Treatment with VEGF-blocking antibodies in the luteal
FIG. 1. Daily E2 concentrations in control cycles, anti-VEGF anti-
body-treated cycles (upper panel), and IgG-treated cycles (lower pan-
el). Data for the control cycles are the mean 6 SE concentrations (open
circles). Day 0 represents the first day of injection of the anti-VEGF
antibody or IgG or, in the control cycles, the day of comparable E2
concentrations. E, Mean of control and preinjection values. For the
anti-VEGF- or IgG- treated cycles (F), individual E2 concentrations up
to the preovulatory E2 peak are shown for six of seven monkeys
responding to the anti-VEGF treatment and the three IgG-treated
monkeys.
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phase decreases endothelial cell proliferation, blocks devel-
opment of the extensive capillary bed, and interferes with
normal luteal function, as judged by decreasing secretion of
progesterone, presumably as a result of the reduction in the
microvasculature. Similar results were reported in the PMS/
hCG-treated rat (25). However, because in the rodent model
the long-term anti-VEGF antibody treatment was started
before initiation of follicular stimulation, it is difficult to
separate interference with follicular maturation from luteal
inhibition by the treatment. Yet, it is important to note that
in our own data from the primate, short-term neutralization
of VEGF during the follicular phase does not interfere with
ovulation and corpus luteum function, as demonstrated by
mean integrated luteal progesterone levels similar to those in
the control menstrual cycles.
In conclusion, we have demonstrated that the angiogenic
factor VEGF is a crucial physiological component in the
process of follicular growth in the nonhuman primate. A
significant delay in completion of the follicular phase occurs
when VEGF activity is neutralized. Our data also indicate
that the menstrual cycles that follow the treatment cycle are
normal, suggesting that the inhibition of ovarian function by
this antiangiogenic compound is temporary.
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